Mankind Pharma
Last updated Jun 19, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
66%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Neurology
- Antiepileptic
Highest priority development: FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Mankind Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 66%
Active Signals
1
Investigate Priority
0
Opportunity Score
15
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 19, 2026Score 15FDA Grants AP Status for Divalproex Sodium ANDA217358 by Mankind Pharma
Neurology · Antiepileptic
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DIVALPROEX SODIUM (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DIVALPROEX SODIUM (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DIVALPROEX SODIUM (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Mankind Pharma right now?
- Which regulatory precedents should Mankind Pharma monitor in Neurology and Antiepileptic?
- How does Regulatory Developments Reshaping Competitive Landscape in Neurology Markets compare to the nearest competitive programs?
- What signals require immediate investigation for Mankind Pharma?
- Summarize the strategic implications of recent developments for Mankind Pharma.
- Where is the greatest uncertainty in Mankind Pharma's competitive positioning?